BROUGHT TO YOU BY:

ETF Portfolio Builder

New

ETF Portfolio Builder

New

CANCvsSBIOETF Comparison

ETF 1

CANC

Tema Oncology ETF

This fund is part of

Tomorrow's Treatments

-1.35%

Full CANC fund page

VS

ETF 2

SBIO

ALPS Medical Breakthroughs ETF

This fund is part of

Tomorrow's Treatments

-1.35%

Full SBIO fund page

Tema Oncology ETF (CANC) and ALPS Medical Breakthroughs ETF (SBIO) belong to the same industry segment: Tomorrow's Treatments. In contrast, SBIO's top sector exposures are Healthcare and Non-Corporate. CANC is more expensive with a Total Expense Ratio (TER) of 0.99%, versus 0.5% for SBIO. CANC is up 19.12% year-to-date (YTD) with +$67M in YTD flows. SBIO performs worse with 4.3% YTD performance, and +$62M in YTD flows. Run a side-by-side ETF comparison of CANC and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.

Find out how industry players manage ETF portfolios. Discover our library of Model portfolios

CANC vs SBIO performance and flow charts

Performance

Cumulative Flows

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Data Services

Historic performance and flows

Data as of 10/23/2026

		1M	3M	YTD	1Y	3Y	5Y
Perf.	CANC SBIO	-0.39%-11.00%	-0.13%-17.10%	+19.12%+4.30%	+38.72%+26.73%	+95.73%+130.96%	n/a+19.37%
Flows	CANC SBIO	+$5M-$10M	+$14M+$21M	+$67M+$62M	+$85M+$79M	+$151M+$45M	-+$6M

Volatility and drawdown

		3M	1Y	3Y	5Y
Volatility	CANC SBIO	+23.58%+31.85%	+23.29%+32.35%	+22.45%+31.52%	n/a+34.22%
Max drawdown	CANC SBIO	-13.09%-29.19%	-13.09%-29.19%	-27.90%-42.12%	n/a-52.50%
Max drawdown duration	CANC SBIO	59d65d	59d65d	441d331d	n/a1479d

Trading data

Create an account to view trading data

Join for free

	CANC	SBIO
Last sale 10/26/2026 at 1:30 PM	$40.99	$53.78
Previous close 10/23/2026	$41.29	$53.38
Consolidated volume 10/23/2026
Average volume 30 days
Average discount or premium 30 days
Average Bid/Ask spread 30 days

Replication quality

Data as of September 30, 2026

1-year trailing difference

Create an account to view replication metrics

Join for free

CANC

is actively managed and doesn’t replicate an index

Create an account to view replication quality

Join for free

	CANC	SBIO
Tracking error
Tracking difference
1 year cumulative return difference
Best
Worst
Daily return difference
Average
Worst

Main metrics

Last update 10/26/2026 at 1:30 PM

Live

Closed

	CANC	SBIO
Last price	$40.99	$53.78
1D performance	-0.73%	+0.74%
AuM	$210.84 M	$183.99 M
E/R	0.99%	0.5%

Characteristics

	CANC	SBIO
Management strategy	Active	Passive
Provider	Tema	ALPS
Benchmark	-	S-Network Medical Breakthroughs Index
N° of holdings	-	104
Asset class	-	Equities
Trailing 12m distribution yield	Join	Join
Inception date	August 15, 2023	December 30, 2014
ESG	No	No

More CANC data on Trackinsight

More SBIO data on Trackinsight

Exposure

Countries

CANC

Data will be available soon

SBIO

USA

89.31%

Other

10.69%

Sectors

CANC

Data will be available soon

SBIO

Healthcare

100.01%

Other

-0.01%

Diversification

CANC

Data will be available soon

SBIO

Total weight of top 15 holdings out of 15

41.55%

Top 15 holdings

Data as of January 1, 1970

CANC

Data will be available soon

SBIO

Crinetics Pharmaceuticals, Inc.

4.60%

Apogee Therapeutics, Inc.

4.29%

CG Oncology, Inc.

3.41%

Travere Therapeutics, Inc.

3.16%

Xenon Pharmaceuticals, Inc.

2.99%

Dianthus Therapeutics, Inc.

2.96%

Oruka Therapeutics, Inc.

2.87%

ACADIA Pharmaceuticals, Inc.

2.54%

Edgewise Therapeutics, Inc.

2.31%

Definium Therapeutics, Inc.

2.23%

Dyne Therapeutics, Inc.

2.16%

Veradermics, Inc.

2.11%

Relay Therapeutics, Inc.

2.05%

Denali Therapeutics, Inc.

1.94%

Amylyx Pharmaceuticals, Inc.

1.93%

Frequently asked questions about CANC and SBIO

How have the CANC and SBIO ETFs performed in 2026?

As of October 23, 2026, CANC is up 19.12% year-to-date (YTD), while SBIO has returned 4.3%. That puts CANC better performer ahead so far this year.

Which ETF is attracting more investor money: CANC or SBIO?

Year-to-date, the CANC ETF saw +$67M in flows, compared to +$62M for SBIO.

Which ETF is more volatile: CANC or SBIO?

Over the past year, CANC had a volatility of 23.29%, while SBIO experienced 32.35%.

Which ETF is bigger: CANC or SBIO?

As of October 23, 2026, CANC holds $210.84 M in assets under management (AUM), while SBIO manages $183.99 M.

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

September 18, 2025

SBIO

Two biotech ETFs to watch for the rest of 2022 and beyond

September 13, 2022

SBIO

CANCvsSBIOETF Comparison

Tema Oncology ETF

ALPS Medical Breakthroughs ETF

CANC vs SBIO performance and flow charts

Performance

Cumulative Flows

Get all the metrics on this page, and more, through a reliable ETF data feed

Countries

Sectors

Diversification

Top 15 holdings

How have the CANC and SBIO ETFs performed in 2026?

As of October 23, 2026, CANC is up 19.12% year-to-date (YTD), while SBIO has returned 4.3%. That puts CANC better performer ahead so far this year.

Which ETF is attracting more investor money: CANC or SBIO?

Year-to-date, the CANC ETF saw +$67M in flows, compared to +$62M for SBIO.

Which ETF is more volatile: CANC or SBIO?

Over the past year, CANC had a volatility of 23.29%, while SBIO experienced 32.35%.

Which ETF is bigger: CANC or SBIO?

As of October 23, 2026, CANC holds $210.84 M in assets under management (AUM), while SBIO manages $183.99 M.

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Two biotech ETFs to watch for the rest of 2022 and beyond

ETFs’ Next Act: From Access to Selection